Supernus Pharmaceuticals (SUPN) Net Income Growth (3y) (2014 - 2026)
Supernus Pharmaceuticals (SUPN) Net Income Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -27.09% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.67 Bn | 2.30 Bn | 185.39 Mn | -313.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -313.27% |
| Dec 31, 2025 | -29.28% |
| Sep 30, 2025 | -202.92% |
| Jun 30, 2025 | 41.96% |
| Mar 31, 2025 | -35.02% |
| Dec 31, 2024 | 84.46% |
| Sep 30, 2024 | 21.36% |
| Jun 30, 2024 | -5.69% |
| Mar 31, 2024 | -70.72% |
| Dec 31, 2023 | -66.32% |
| Sep 30, 2023 | -33.88% |
| Mar 31, 2023 | -7.65% |
| Dec 31, 2022 | -8.35% |
| Sep 30, 2022 | -60.72% |
| Jun 30, 2022 | -37.83% |
| Mar 31, 2022 | 11.79% |
| Dec 31, 2021 | -54.48% |
| Sep 30, 2021 | -8.35% |
| Jun 30, 2021 | -8.27% |
| Mar 31, 2021 | -39.99% |